Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.09. | PolyPid: Starke Phase-3-Daten für D-PLEX100 - US-Partner für Markteinführung gesucht | 2 | Investing.com Deutsch | ||
30.09. | PolyPid Ltd.: PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress | 1 | GlobeNewswire (USA) | ||
16.09. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.09. | PolyPid Ltd.: PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX100 | 1 | GlobeNewswire (USA) | ||
21.08. | Earnings Call: PolyPid meldet für Q2 2025 höheren Verlust, Aktie gibt nach | 2 | Investing.com Deutsch | ||
13.08. | PolyPid Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
13.08. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results | 122 | GlobeNewswire (Europe) | Positive Phase 3 SHIELD II Trial Results - D-PLEX100 successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting... ► Artikel lesen | |
POLYPID Aktie jetzt für 0€ handeln | |||||
12.08. | PolyPid appoints Nurit Tweezer-Zaks as chief medical officer | 2 | Seeking Alpha | ||
12.08. | PolyPid Names Nurit Tweezer-Zaks As CMO | 1 | RTTNews | ||
12.08. | PolyPid appoints Dr. Tweezer-Zaks as chief medical officer | 1 | Investing.com | ||
12.08. | PolyPid Ltd.: PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer | 225 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced... ► Artikel lesen | |
12.08. | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
30.07. | PolyPid Ltd.: PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025 | 1 | GlobeNewswire (USA) | ||
15.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 13 | SEC Filings | ||
15.07. | PolyPid stellt Plattform für 60-tägige GLP-1-Wirkstofffreisetzung vor | 1 | Investing.com Deutsch | ||
15.07. | PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment | 3 | Investing.com | ||
25.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
17.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
17.06. | PolyPid stock price target lowered to $14 at JMP on warrant dilution | 4 | Investing.com | ||
17.06. | PolyPid Ltd.: PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 89,65 | -2,18 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
EVOTEC | 6,866 | +2,08 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
CUREVAC | 4,610 | -0,52 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
AMGEN | 252,35 | -1,08 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
VIKING THERAPEUTICS | 29,970 | +10,82 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule
VK2735 Phase 1 Maintenance... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,512 | +0,79 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,439 | -5,79 % | NurExone setzt neue Standards: Patente und Qualität als Fundament für den nächsten Schritt | ||
ABIVAX | 77,50 | +0,26 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
IBIO | 1,120 | -6,67 % | Why Did iBio Shares Surge Over 11% In Pre-Market Trading? | ||
ARROWHEAD PHARMACEUTICALS | 31,960 | -1,45 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
VOYAGER THERAPEUTICS | 3,990 | -2,83 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
OPGEN | 2,600 | 0,00 % | OPGEN INC - 10-Q, Quarterly Report | ||
MEREO BIOPHARMA | 1,770 | -1,39 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
APELLIS PHARMACEUTICALS | 23,550 | -0,65 % | Apellis Pharmaceuticals, Inc.: New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week | Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of... ► Artikel lesen | |
CYBIN | 5,100 | +2,00 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen |